针对G和M2的单剂量鼻内腺病毒RSV疫苗。

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-07-01 DOI:10.1038/s41541-025-01186-x

Eunju Jang, Serin Lee, Jiyu Han, Jun Chang

引用次数: 0

摘要

研制了以呼吸道合胞病毒G蛋白和M2蛋白为靶点的腺载体疫苗。单次鼻内疫苗接种诱导了强大的G蛋白特异性IgG和IgA反应，以及m2特异性CD8+ t细胞免疫，并提供了对RSV A和B感染的保护。这些发现表明，这种疫苗组合具有有效预防RSV的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2.

We have developed adenovector-based vaccines targeting G and M2 protein of respiratory syncytial virus. Single intranasal vaccination induced robust G protein-specific IgG and IgA responses, as well as M2-specific CD8⁺ T-cell immunity, and provided protection against RSV A and B infection. These findings suggest that this vaccine combination holds promising potential for effective RSV prevention.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.